US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Belgian biotech firm ThromboGenics, which is focussed on developing novel medicines for back of the eye diseases and focused on diabetic eye disease, today announced it has strengthened its senior leadership team, attracting former executives from Allergan and Novartis. 8 November 2017
Chirfi Guindo has been appointed executive vice president and head of global marketing, market access and customer innovation at US biotech major Biogen. 3 November 2017
Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy treatments that are changing cancer care, has announced several key leadership appointments to further the company’s continued growth and expansion. 27 October 2017
Belgian biotech firm Ablynx saw its shares gain 2.3% to 18.28 euros as markets opened this morning and following the announcement that it is establishing a subsidiary in the USA. 16 October 2017
Norbert Oppitz has been appointed senior vice president for the newly-established business area Specialty Care at Nordic drugmaker Swedish Orphan Biovitrum, and will be part of Sobi’s executive leadership team. 6 October 2017
Massachusetts-based Rubius Therapeutics has shaken up its executive team, with new appointments in the firm’s medical, financial, legal and HR divisions. 28 September 2017
A former researcher at Amgen has been named as the new chief scientific officer of UK-based cellular immunotherapy company Cell Medica. 18 September 2017
Alexandre Sudarskis, chief executive of privately-held Swiss biopharma firm Neovii Pharmaceuticals will step down from this post having reached retirement age. 15 September 2017
US ophthalmology specialist Ocular Therapeutix (Nasdaq: OCUL) today announced the appointment of Michael Goldstein as chief medical officer. 8 September 2017
UK-based artificial intelligence firm BenevolentAI has hired Ian Churcher as VP of drug discovery & preclinical development for its bioscience subsidiary, BenevolentBio. 22 August 2017
Ireland-headquartered Shire has announced changes to its executive committee, as it progresses its strategy to sharpen its focus as a leader in rare diseases. 21 August 2017
UK and USA-based clinical-stage biotech Orchard Therapeutics today announces the appointment of Mark Rothera as president and chief executive. 10 August 2017
US clinical-stage biotech firm Pfenex today announced the appointment of Evert (Eef) Schimmelpennink as chief executive, president, and secretary effective August 3, 2017. 3 August 2017